title: Efficacy of yeast-derived recombinant hepatitis B vaccine after being used for 12 years in highly endemic areas in China.
abstract: OBJECTIVE
  To evaluate the long-term efficacy and duration of yeast-derived recombinant hepatitis B vaccine in hepatitis B virus (HBV)-endemic areas.
  
  
  METHODS
  A cross-sectional investigation was carried out in five HBV-endemic areas. Children who were born between 1997 and 2008 and vaccinated with yeast-derived recombinant hepatitis B vaccine were selected. Serum samples were taken to test HBV infection markers by microparticle enzyme immunoassay, and the results were compared to those before vaccination.
  
  
  RESULTS
  7066 subjects were enrolled. The average adjusted hepatitis B surface antigen (HBsAg) prevalence was 1.02%. HBV core antibody (anti-HBc) prevalence was 3.54%. The overall percentage of HBsAg(-)&Anti-HBc(-)&Anti-HBs(+) was 61.34%. With time after immunization, the percentage annually decreases from 86.11% in 2008 to 49.80% in 1997. Geometric mean concentration (GMC) of anti-HBs decreased significantly annually. The portion of GMC=100-999.9 mIU/ml was 48.0% in 2008, and decreased to 16.7% in 1997.
  
  
  CONCLUSIONS
  HBsAg prevalence decreased dramatically. This shows that the yeast-derived recombinant hepatitis B vaccine is effective and stable after being used for 12 years in HBV-endemic areas. It is not suggested to carry out booster immunization.
authors.affiliation: Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.
authors.forename: Liping
authors.initials: L
authors.lastname: Shen
authors.forename: Fuzhen
authors.initials: F
authors.lastname: Wang
authors.forename: Feng
authors.initials: F
authors.lastname: Wang
authors.forename: Fuqiang
authors.initials: F
authors.lastname: Cui
authors.forename: Shuang
authors.initials: S
authors.lastname: Zhang
authors.forename: Hui
authors.initials: H
authors.lastname: Zheng
authors.forename: Yong
authors.initials: Y
authors.lastname: Zhang
authors.forename: Xiaofeng
authors.initials: X
authors.lastname: Liang
authors.forename: Shengli
authors.initials: S
authors.lastname: Bi
mesh_terms: D002681:China / Q000453:epidemiology; D003430:Cross-Sectional Studies; D005260:Female; D006509:Hepatitis B / Q000453:epidemiology / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000097:blood; D006514:Hepatitis B Surface Antigens / Q000097:blood; D017325:Hepatitis B Vaccines / Q000096:biosynthesis / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D008297:Male; D015995:Prevalence; D014614:Vaccines, Synthetic / Q000096:biosynthesis / Q000276:immunology / Q000627:therapeutic use
chemical_list: D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D014614:Vaccines, Synthetic